[Ductal carcinoma of the prostate: impact on survival and therapeutic controversies of a rare XXXX ].

@entity1 @entity263 @entity5 @entity2461 @entity420
@entity263 is a disease with a variable clinical course. The possible impact on oncological outcome of @entity263 has not been established yet, especially for @entity420 due to its low frequency, so that its clinical management is not well codified. The disease occurs more often already at an advanced stage of diagnosis, with clinically detectable @entity5 and advanced pathological stage, partly because of the lack of specific @entity5 markers, given the poor correlation between @entity2461 and PSA values. In the period between 1997 and 2010 56 @entity1 with @entity2461 on a total of 1265 new diagnoses of @entity5 were identified, for an overall incidence of 4.5%. 41 @entity1 (75%) had a @entity2461 type II histology, while 15 @entity1 (25%) a @entity2461 type I (pure form). Generally, a surgical treatment was carried out in @entity1 with life expectancy greater than 10/15 years/under 70 years of age, non-metastatic @entity5 and found to be liable to local resection; radiation therapy was given with 70 Gy in cases with a shorter life expectancy and/or an illness judged unresectable for local extension; hormonal therapy was indicated in all other clinical situations. For all @entity1 , the clinical and pathologic data and follow-ups were re-evaluated. The overall survival and disease-free survival were then analyzed. Given the low incidence of this pathology the relevant literature is poor and therefore the therapeutic approach is not univocal. This paper retrospectively reviews our experience with @entity263 .
